Currently, most of the above-mentioned checkpoint inhibitor clinical trials in meningiomas investigate the predictive value of different immune biomarkers such as PD-L1 and PD-1 immunohistochemical staining in the tumor and immunophenotypes of tissue infiltrating lymphocytes. This evidence concerns the gene CD274 and meningioma.